SCHEMBL3877565

SCHEMBL3877565

NC(=O)c1[nH]c2cccnc2c1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 3/20 0.54
TEK Q02763 2/20 0.48
FLT1 P17948 2/20 0.48
NTRK1 P04629 1/20 0.47
RAF1 P04049 1/20 0.46
KDR P35968 7/20 0.44
BRAF P15056 1/20 0.44
PDGFRB P09619 1/20 0.44
KIT P10721 2/20 0.44
FLT3 P36888 2/20 0.44
ABL1 P00519 1/20 0.44
LCK P06239 1/20 0.44
FYN P06241 1/20 0.44
CSF1R P07333 1/20 0.44
LYN P07948 1/20 0.44
SRC P12931 1/20 0.44
FLT4 P35916 1/20 0.44
BLK P51451 1/20 0.44
P2RY1 P47900 4/20 0.43
TRPV1 Q8NER1 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3878426 0.90 KDR (0.54) RIPK1TEKFLT1NTRK1KDR
SCHEMBL3878842 0.89 MTOR (0.47) KDRPDGFRBTRPV1
SCHEMBL3880957 0.87 BRAF (0.53) TEKFLT1RAF1KDRBRAF
SCHEMBL1878220 0.87 RIPK1 (0.59) RIPK1TEKFLT1NTRK1RAF1
SCHEMBL3885672 0.87 TRPV1 (0.54) RIPK1TEKRAF1KDRBRAF
SCHEMBL3885329 0.87 KDR (0.59) RIPK1TEKFLT1NTRK1KDR
SCHEMBL3994496 0.85 RIPK1 (0.52) RIPK1FLT1NTRK1KDRBRAF
SCHEMBL3881695 0.83 KDR (0.48) RIPK1FLT1KDRKITFLT3
SCHEMBL1884927 0.83 RIPK1 (0.54) RIPK1TEKFLT1NTRK1RAF1
SCHEMBL3881680 0.81 RIPK1 (0.54) RIPK1FLT1KDRPDGFRBKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070259910-A1 Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use AVENTIS PHARMA S.A. (FR) 2007-11-08 US claimed
EP-1841762-A1 SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE Aventis Pharma S.A. (FR) 2007-10-10 EP claimed
WO-2006061493-A1 SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AVENTIS PHARMA S.A. (FR) 2006-06-15 WO claimed
US-7566736-B2 Substituted indoles, compositions containing them, method for the production thereof and their use AVENTIS PHARMA S.A. (FR) 2009-07-28 US disclosed
US-7566736-B2 Substituted indoles, compositions containing them, method for the production thereof and their use AVENTIS PHARMA S.A. (FR) 2009-07-28 US disclosed
US-7566736-B2 Substituted indoles, compositions containing them, method for the production thereof and their use AVENTIS PHARMA S.A. (FR) 2009-07-28 US disclosed
US-20070259910-A1 Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use AVENTIS PHARMA S.A. (FR) 2007-11-08 US disclosed
US-20070259910-A1 Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use AVENTIS PHARMA S.A. (FR) 2007-11-08 US disclosed
US-20070259910-A1 Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use AVENTIS PHARMA S.A. (FR) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259910-A1 Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use IDO1, RB1, IDO2 RIPK1 2658/4885TEK 2638/4885FLT1 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.